<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=2">
<meta name="theme-color" content="#222">
<meta name="generator" content="Hexo 5.2.0">
  <link rel="apple-touch-icon" sizes="180x180" href="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/Logo2.ico">
  <link rel="icon" type="image/png" sizes="32x32" href="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/Logo2.ico">
  <link rel="icon" type="image/png" sizes="16x16" href="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/Logo2.ico">
  <link rel="mask-icon" href="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/Logo2.ico" color="#222">

<link rel="stylesheet" href="/css/main.css">

<link rel="stylesheet" href="//fonts.googleapis.com/css?family=Lato:300,300italic,400,400italic,700,700italic|14px:300,300italic,400,400italic,700,700italic&display=swap&subset=latin,latin-ext">
<link rel="stylesheet" href="/lib/font-awesome/css/all.min.css">
  <link rel="stylesheet" href="//cdn.jsdelivr.net/gh/fancyapps/fancybox@3/dist/jquery.fancybox.min.css">
  <link rel="stylesheet" href="/lib/pace/pace-theme-corner-indicator.min.css">
  <script src="/lib/pace/pace.min.js"></script>

<script id="hexo-configurations">
    var NexT = window.NexT || {};
    var CONFIG = {"hostname":"zhenyumi.github.io","root":"/","scheme":"Gemini","version":"7.8.0","exturl":false,"sidebar":{"position":"left","display":"post","padding":18,"offset":12,"onmobile":false},"copycode":{"enable":true,"show_result":true,"style":"mac"},"back2top":{"enable":true,"sidebar":false,"scrollpercent":true},"bookmark":{"enable":true,"color":"#000000","save":"auto"},"fancybox":{"enable":true,"caption":false},"mediumzoom":false,"lazyload":true,"pangu":true,"comments":{"style":"valine","active":null,"storage":true,"lazyload":false,"nav":null},"algolia":{"hits":{"per_page":10},"labels":{"input_placeholder":"Search for Posts","hits_empty":"We didn't find any results for the search: ${query}","hits_stats":"${hits} results found in ${time} ms"}},"localsearch":{"enable":true,"trigger":"auto","top_n_per_article":1,"unescape":false,"preload":false},"motion":{"enable":true,"async":true,"transition":{"post_block":"slideDownBigIn","post_header":"slideDownIn","post_body":"slideDownIn","coll_header":"slideLeftIn","sidebar":"slideUpIn"}},"path":"./public/search.xml"};
  </script>

  <meta name="description" content="Therapy and drugs for cancer">
<meta property="og:type" content="article">
<meta property="og:title" content="L14 Cancer Pharmacology">
<meta property="og:url" content="https://zhenyumi.github.io/posts/6c8073ce.html">
<meta property="og:site_name" content="鹘横海">
<meta property="og:description" content="Therapy and drugs for cancer">
<meta property="og:locale" content="zh_CN">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202224854.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202242643.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202347631.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202624981.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202634016.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202727564.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202748270.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203057109.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203121832.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203413169.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203426462.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203721454.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203946159.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204007399.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204012617.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204127022.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204921275.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204932275.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135050395.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135059029.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135104615.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135120792.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525141253371.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525141330998.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142139737.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142258974.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142315443.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142322670.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143532638.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143608863.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143659938.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143741516.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143752339.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143843235.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164029948.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164043950.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164053841.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164345230.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164941329.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164949067.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170126311.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170148030.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170709521.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525171044816.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172442824.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172655578.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172934902.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172950715.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173019126.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173032440.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173303528.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173917874.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525174006082.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525174038754.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175114183.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175240334.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525152058913.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175504627.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175644835.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175715808.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175724146.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175734353.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175742320.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175753074.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184614504.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184705780.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184756462.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184908253.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184957613.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185018602.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185127839.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185145400.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185258096.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185414485.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185436414.png">
<meta property="article:published_time" content="2021-06-01T07:47:14.000Z">
<meta property="article:modified_time" content="2021-06-01T07:47:14.000Z">
<meta property="article:author" content="向海">
<meta property="article:tag" content="Molecular Pharmacology">
<meta name="twitter:card" content="summary">
<meta name="twitter:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202224854.png">

<link rel="canonical" href="https://zhenyumi.github.io/posts/6c8073ce.html">


<script id="page-configurations">
  // https://hexo.io/docs/variables.html
  CONFIG.page = {
    sidebar: "",
    isHome : false,
    isPost : true,
    lang   : 'zh-CN'
  };
</script>

  <title>L14 Cancer Pharmacology | 鹘横海</title>
  


  <script data-pjax>
    var _hmt = _hmt || [];
    (function() {
      var hm = document.createElement("script");
      hm.src = "https://hm.baidu.com/hm.js?aa95e0eb65e5b58f6500e4de221c0f67";
      var s = document.getElementsByTagName("script")[0];
      s.parentNode.insertBefore(hm, s);
    })();
  </script>




  <noscript>
  <style>
  .use-motion .brand,
  .use-motion .menu-item,
  .sidebar-inner,
  .use-motion .post-block,
  .use-motion .pagination,
  .use-motion .comments,
  .use-motion .post-header,
  .use-motion .post-body,
  .use-motion .collection-header { opacity: initial; }

  .use-motion .site-title,
  .use-motion .site-subtitle {
    opacity: initial;
    top: initial;
  }

  .use-motion .logo-line-before i { left: initial; }
  .use-motion .logo-line-after i { right: initial; }
  </style>
</noscript>

</head>

<body itemscope itemtype="http://schema.org/WebPage">
  <div class="container use-motion">
    <div class="headband"></div>

    <header class="header" itemscope itemtype="http://schema.org/WPHeader">
      <div class="header-inner"><div class="site-brand-container">
  <div class="site-nav-toggle">
    <div class="toggle" aria-label="切换导航栏">
      <span class="toggle-line toggle-line-first"></span>
      <span class="toggle-line toggle-line-middle"></span>
      <span class="toggle-line toggle-line-last"></span>
    </div>
  </div>

  <div class="site-meta">

    <a href="/" class="brand" rel="start">
      <span class="logo-line-before"><i></i></span>
      <h1 class="site-title">鹘横海</h1>
      <span class="logo-line-after"><i></i></span>
    </a>
      <p class="site-subtitle" itemprop="description">Hope tomorrow is still shining.  Today is another day.</p>
  </div>

  <div class="site-nav-right">
    <div class="toggle popup-trigger">
        <i class="fa fa-search fa-fw fa-lg"></i>
    </div>
  </div>
</div>




<nav class="site-nav">
  <ul id="menu" class="main-menu menu">
        <li class="menu-item menu-item-home">

    <a href="/" rel="section"><i class="fa fa-home fa-fw"></i>首页</a>

  </li>
        <li class="menu-item menu-item-about">

    <a href="/about/" rel="section"><i class="fa fa-user fa-fw"></i>关于</a>

  </li>
        <li class="menu-item menu-item-tags">

    <a href="/tags/" rel="section"><i class="fa fa-tags fa-fw"></i>标签<span class="badge">23</span></a>

  </li>
        <li class="menu-item menu-item-categories">

    <a href="/categories/" rel="section"><i class="fa fa-th fa-fw"></i>分类<span class="badge">23</span></a>

  </li>
        <li class="menu-item menu-item-archives">

    <a href="/archives/" rel="section"><i class="fa fa-archive fa-fw"></i>归档<span class="badge">186</span></a>

  </li>
        <li class="menu-item menu-item-留言板">

    <a href="/%E7%95%99%E8%A8%80%E6%9D%BF/" rel="section"><i class="fas fa-chalkboard-teacher fa-fw"></i>留言板</a>

  </li>
      <li class="menu-item menu-item-search">
        <a role="button" class="popup-trigger"><i class="fa fa-search fa-fw"></i>搜索
        </a>
      </li>
  </ul>
</nav>



  <div class="search-pop-overlay">
    <div class="popup search-popup">
        <div class="search-header">
  <span class="search-icon">
    <i class="fa fa-search"></i>
  </span>
  <div class="search-input-container">
    <input autocomplete="off" autocapitalize="off"
           placeholder="搜索..." spellcheck="false"
           type="search" class="search-input">
  </div>
  <span class="popup-btn-close">
    <i class="fa fa-times-circle"></i>
  </span>
</div>
<div id="search-result">
  <div id="no-result">
    <i class="fa fa-spinner fa-pulse fa-5x fa-fw"></i>
  </div>
</div>

    </div>
  </div>

</div>
    </header>

    
  <div class="back-to-top">
    <i class="fa fa-arrow-up"></i>
    <span>0%</span>
  </div>
  <div class="reading-progress-bar"></div>
  <a role="button" class="book-mark-link book-mark-link-fixed"></a>


    <main class="main">
      <div class="main-inner">
        <div class="content-wrap">
          

          <div class="content post posts-expand">
            

    
  
  
  <article itemscope itemtype="http://schema.org/Article" class="post-block" lang="zh-CN">
    <link itemprop="mainEntityOfPage" href="https://zhenyumi.github.io/posts/6c8073ce.html">

    <span hidden itemprop="author" itemscope itemtype="http://schema.org/Person">
      <meta itemprop="image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/pixil-frame-0.png">
      <meta itemprop="name" content="向海">
      <meta itemprop="description" content="希望能活的久一点">
    </span>

    <span hidden itemprop="publisher" itemscope itemtype="http://schema.org/Organization">
      <meta itemprop="name" content="鹘横海">
    </span>
      <header class="post-header">
        <h1 class="post-title" itemprop="name headline">
          L14 Cancer Pharmacology
        </h1>

        <div class="post-meta">
            <span class="post-meta-item">
              <span class="post-meta-item-icon">
                <i class="far fa-calendar"></i>
              </span>
              <span class="post-meta-item-text">发表于</span>

              <time title="创建时间：2021-06-01 15:47:14" itemprop="dateCreated datePublished" datetime="2021-06-01T15:47:14+08:00">2021-06-01</time>
            </span>
            <span class="post-meta-item">
              <span class="post-meta-item-icon">
                <i class="far fa-folder"></i>
              </span>
              <span class="post-meta-item-text">分类于</span>
                <span itemprop="about" itemscope itemtype="http://schema.org/Thing">
                  <a href="/categories/Academic-Notebook/" itemprop="url" rel="index"><span itemprop="name">Academic Notebook</span></a>
                </span>
                  ，
                <span itemprop="about" itemscope itemtype="http://schema.org/Thing">
                  <a href="/categories/Academic-Notebook/Molecular-Pharmacology/" itemprop="url" rel="index"><span itemprop="name">Molecular Pharmacology</span></a>
                </span>
            </span>

          
            <span class="post-meta-item" title="阅读次数" id="busuanzi_container_page_pv" style="display: none;">
              <span class="post-meta-item-icon">
                <i class="fa fa-eye"></i>
              </span>
              <span class="post-meta-item-text">阅读次数：</span>
              <span id="busuanzi_value_page_pv"></span>
            </span>
  
  <span class="post-meta-item">
    
      <span class="post-meta-item-icon">
        <i class="far fa-comment"></i>
      </span>
      <span class="post-meta-item-text">Valine：</span>
    
    <a title="valine" href="/posts/6c8073ce.html#valine-comments" itemprop="discussionUrl">
      <span class="post-comments-count valine-comment-count" data-xid="/posts/6c8073ce.html" itemprop="commentCount"></span>
    </a>
  </span>
  
  <br>
            <span class="post-meta-item" title="本文字数">
              <span class="post-meta-item-icon">
                <i class="far fa-file-word"></i>
              </span>
                <span class="post-meta-item-text">本文字数：</span>
              <span>22k</span>
            </span>

        </div>
      </header>

    
    
    
    <div class="post-body" itemprop="articleBody">

      
        <h1 id="一-cancer-biology"><a class="markdownIt-Anchor" href="#一-cancer-biology"></a> 一、Cancer Biology</h1>
<h2 id="what-is-cancer"><a class="markdownIt-Anchor" href="#what-is-cancer"></a> What is Cancer</h2>
<p>Cancer or Neoplasm is an abnormal mass of tissue as a result of abnormal proliferation of cells.</p>
<p>Neo-plasm: novel swelling mass in the body</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202224854.png" alt="image-20210524202224854" style="zoom:100%;" />
**Some neoplasms do not form a tumor**
<ul>
<li>Some blood cancers such as leukemia don’t form a tumor, it widely spread in the bloodstream and bone marrow.</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202242643.png" alt="image-20210524202242643" style="zoom:67%;" />
<h2 id="what-are-the-difference-between-a-normal-and-cancer-cells"><a class="markdownIt-Anchor" href="#what-are-the-difference-between-a-normal-and-cancer-cells"></a> What are the difference between a normal and cancer cells</h2>
<h3 id="1-cell-shape"><a class="markdownIt-Anchor" href="#1-cell-shape"></a> 1. Cell shape</h3>
<p>Normal cells:</p>
<ul>
<li>Committed Cells—divide only <u>a defined number of times</u>, and are <u>limited in capacity for self-renewal</u></li>
<li>Specialized Cells—carry out <strong>organ function</strong> and are incapable of cell division</li>
<li><strong>Restricted</strong> to its functional area</li>
</ul>
<p><strong>Normal and Cancer Cell Structure</strong>:</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202347631.png" alt="image-20210524202347631" style="zoom:100%;" />
### 2. Genetic Aberrations
<p><strong>Genetic Aberrations</strong></p>
<ul>
<li>Chromosomal Translocation</li>
<li>Chromosomal Deletion</li>
<li>Gene mutation</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202624981.png" alt="image-20210524202624981" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202634016.png" alt="image-20210524202634016" style="zoom:100%;" />
#### Chromosomal Translocation
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202727564.png" alt="image-20210524202727564" style="zoom:100%;" />
+ Philadelphia chromosome
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202748270.png" alt="image-20210524202748270" style="zoom:100%;" />
## How does cancer take place (Causes of cancer)
<ol>
<li>Sex: male&gt;women</li>
<li>Age: most cancers in people&gt; 50 YO</li>
<li>Race</li>
<li>Genetic predisposition</li>
<li>Environment - living and warking</li>
</ol>
<ul>
<li>Chemicals</li>
<li>Viruses</li>
</ul>
<ol start="6">
<li>Lifestyle—smoking, alcoholism, preserved food, BBQ…</li>
</ol>
<h3 id="1-polluting-environment"><a class="markdownIt-Anchor" href="#1-polluting-environment"></a> 1. Polluting Environment</h3>
<p><strong>Ionizing radiation</strong></p>
<ul>
<li>Acute leukemia</li>
<li>Thyroid cancer</li>
<li>Breast cancer</li>
<li>Lung cancer</li>
<li>Basal cell skin cancers</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203057109.png" alt="image-20210524203057109" style="zoom:100%;" />
<p><strong>Chemical exposure:</strong></p>
<ul>
<li>azo dyes</li>
<li>aflatoxins</li>
<li>asbestos</li>
<li>benzene</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203121832.png" alt="image-20210524203121832" style="zoom:100%;" />
#### Azo Dyes
<p>synthetic colours that contain an azo group, - N=N-, as part of the structure. Azo groups do not occur naturally</p>
<p>Azo dyes account for approximately 60-70% of all dyes used in food and textile manufacture.</p>
<p>Most colored textile and leather articles are treated with azo dyes and pigments</p>
<p>Bladder cancer (dye factory workers, Azo dye workers still have a tremendous increase in urothelial cancer</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203413169.png" alt="image-20210524203413169" style="zoom:100%;" />
#### Oncovirus: that induce cancers
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203426462.png" alt="image-20210524203426462" style="zoom:100%;" />
<p><strong>DNA Viruses</strong></p>
<ul>
<li>Epstein-Barr virus → Burkitt’s lymphoma</li>
<li>Hepatitis B virus → liver cancer</li>
<li>Human papilloma viruses → cervical cancer</li>
<li>Human herpes virus-8 → Kaposi sarcoma</li>
</ul>
<p><strong>RNA Viruses</strong></p>
<ul>
<li>Human T lymphotrophic virus type 1 (<strong>HTLV-I</strong>), a retrovirus, → T-cell leukemia.</li>
<li>Hepatitis C virus → liver cancer</li>
</ul>
<h4 id="lifestyles"><a class="markdownIt-Anchor" href="#lifestyles"></a> Lifestyles</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203721454.png" alt="image-20210524203721454" style="zoom:100%;" />
+ Smoking
+ Alcoholism
+ Preserved food
+ BBQ
<h3 id="2-pathogenesis-of-neoplasia"><a class="markdownIt-Anchor" href="#2-pathogenesis-of-neoplasia"></a> 2. Pathogenesis of Neoplasia</h3>
<p>Cancer development can begin with a brief exposure (hours or days) to a chemical into an activated form and the chemical need not be present ever again</p>
<p>However, DNA is altered via mutagens including chemical carcinogens, viruses, and radiation. This mutations is inherted by at least one cell division (intiation).</p>
<p>This mutation mainly lead to activation of proto-oncogene into oncogenes (leading to uncontrolled cell proliferation) and/or inactivation of tumor suppressor genes (leading to resistance to apoptosis.)</p>
<p>Upon exposure to other epigenetic factors (hormones, cocarcinogens, immunosuppressant…which themselves are non carcinogenic) tumor growth is promoted (promotion)</p>
<h4 id="initiation"><a class="markdownIt-Anchor" href="#initiation"></a> Initiation</h4>
<p>Initiation point at which an irreversible alteration, usually genetic, is introduced into a target cell</p>
<p>Initiation:</p>
<ol>
<li>is essentially irreversible</li>
<li>caused only by carcinogenic compounds</li>
<li>occurs rapidly after carcinogen exposure</li>
<li>alone does not result in tumor formation</li>
</ol>
<h4 id="promotion"><a class="markdownIt-Anchor" href="#promotion"></a> Promotion</h4>
<p>Promotion is the process whereby an initiated tissue or organ develop focal proliferations and it requires the presence of continuous stimulation.</p>
<p>Promotion:</p>
<ol>
<li>reversible</li>
<li>acts only after exposure to an initiating agent</li>
<li>requires repeated administration of a promoter</li>
<li>is not carcinogenic in itself</li>
</ol>
<hr />
<p>Etiology and Pathogenesis of Neoplasia Initiation and Promotion</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203946159.png" alt="image-20210524203946159" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204007399.png" alt="image-20210524204007399" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204012617.png" alt="image-20210524204012617" style="zoom:100%;" />
# 二、Principle and strategy for cancer therapy
<h2 id="cancer-therapeutic-modalities"><a class="markdownIt-Anchor" href="#cancer-therapeutic-modalities"></a> Cancer Therapeutic Modalities</h2>
<table>
<thead>
<tr>
<th>Name</th>
<th>Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>Isolated <strong>solid</strong> cancers</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>Almost <strong>all cases,</strong> in combined with other treatments. It alone cure 10-15% of all patients.</td>
</tr>
<tr>
<td>Radiation therapy</td>
<td>Used for <strong>half of all cases</strong> to either cure or improve the symptoms of cancer.</td>
</tr>
<tr>
<td>Palliative care</td>
<td>Symptom management</td>
</tr>
</tbody>
</table>
<h2 id="the-log-kill-hypothesis"><a class="markdownIt-Anchor" href="#the-log-kill-hypothesis"></a> The log-kill hypothesis</h2>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204127022.png" alt="image-20210524204127022" style="zoom:100%;" />
+ Infrequent scheduling of treatment courses with low (1 log kill) dosing and a late start prolongs survival but does not cure the patient (i.e., kill rate < growth rate)
+ More intensive and frequent treatment, with adequate (2 log kill) dosing and an earlier start is successful (i.e., kill rate > growth rate)
+ Early surgical removal of the primary tumour decreases the tumour burden. Chemotherapy will remove persistant secondary tumours, and the total duration of therapy does not have to be as long as when chemotherapy alone is used.
<h2 id="treatment-strategies"><a class="markdownIt-Anchor" href="#treatment-strategies"></a> Treatment strategies</h2>
<p>Surgery + Radiotherapy + Chemotherapy</p>
<p>Combined Chemotherapy: various classes of drugs in combination</p>
<ul>
<li><strong>MP</strong>: Melphalan, prednisone</li>
<li><strong>VAD</strong>: Vincristine, Adriamycin, dexamethasone</li>
<li><strong>CHOP</strong>: Cyclophosphomide, doxorubicin, vincristine, prednisone</li>
</ul>
<p>Correct selection of drugs in a regimen can result in decreased development of resistance, synergistic effects and decreased toxic effects.</p>
<p>Drug categories:</p>
<p><strong>Cell Cycle Specifc (CCS)</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimetabolites</td>
<td>Capecitabine, Cytarabine, Fludarabine, 5-Fluorouracil, Gemcitabine</td>
</tr>
<tr>
<td>Antitumor antibiotic</td>
<td>Bleomycin</td>
</tr>
<tr>
<td>Epipodophyllotoxins</td>
<td>Etoposide, Teniposide</td>
</tr>
<tr>
<td>Taxanes</td>
<td>Docetexel, Paclitaxel</td>
</tr>
<tr>
<td>Vinca Alkaloids</td>
<td>Vinblastine, Vincristine</td>
</tr>
</tbody>
</table>
<p><strong>Cell Cycle NonSpecifc (CCNS)</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating agents</td>
<td>Busulfan, Carmustine, Melphalan, Thiotepa</td>
</tr>
<tr>
<td>Anthracyclines</td>
<td>Daunorubucin, Doxorubicin, Idarubicin</td>
</tr>
<tr>
<td>Antitumor Antibiotics</td>
<td>Dactinomycin, Mtomycin</td>
</tr>
<tr>
<td>Camptothecins</td>
<td>Irinotecan</td>
</tr>
<tr>
<td>Platinum analogs</td>
<td>Cisplatin, Carboplatin</td>
</tr>
</tbody>
</table>
<h2 id="problems-associated-with-chemotherapy"><a class="markdownIt-Anchor" href="#problems-associated-with-chemotherapy"></a> Problems associated with chemotherapy</h2>
<h3 id="1-resistance-to-chemotherapy"><a class="markdownIt-Anchor" href="#1-resistance-to-chemotherapy"></a> 1. Resistance to chemotherapy</h3>
<p><strong>Resistance to chemotherapy may develop by several mechanisms:</strong></p>
<ul>
<li>Decrease in the amount of drug uptake by cancer cells
<ul>
<li>E.G. Methotrexate</li>
</ul>
</li>
<li>Increase in the amount of drug removed by cancer cells. (Transporters=P-glycoprotein).
<ul>
<li>E.G. Vinblastine ,doxorubicin, bleomycin ,etapsoid….</li>
</ul>
</li>
<li>Decrease or alteration in target molecule sensitivity – this is caused by mutation in the molecule targeted by the drug
<ul>
<li>E.G. Methotrexate,Mercaptopurine,doxorubicin</li>
</ul>
</li>
<li>Increase in DNA repair ability of the cell via an increased expression of DNA repairing enzymes.
<ul>
<li>E.G. Alkylating agent</li>
</ul>
</li>
</ul>
<h4 id="resistance-mechanisms"><a class="markdownIt-Anchor" href="#resistance-mechanisms"></a> Resistance Mechanisms</h4>
<p>Alterations that affect the <strong>mechanism of action</strong> of the drugs:</p>
<ol>
<li>increased DNA repair: crosslinking agents, bleorsycin</li>
<li>formation of trapping agents: crosslinking agents</li>
<li>changes in target proteins (esp. enzymes): drugs that prevent DNA synthesis, some natural products, signal transduction inhibitors, antibodies</li>
</ol>
<p>Alterations that affect drug concentrations <strong>inside the tumour cell</strong>:</p>
<ol>
<li>decreased activation of prodrugs: <strong>5-fluorouracil, cyclophosphamide, trinotecan</strong></li>
<li>increased inactivation: antimetabolites (esp. purine analogues)</li>
<li>decreased accumulation:
<ol>
<li>decreased transport into the cell: folate analogues, <strong>mechlorethamine</strong> platins</li>
<li>increased export from the cell due upregulation of efflux transporters(esp <u>increased P-glycoprotein</u>) natural products(esp. anthracyclines, vinca alkaloids taxanes, epipodophyllotoxins)
<ul>
<li>this is an important cause of <strong>multidrug resistance</strong></li>
</ul>
</li>
</ol>
</li>
</ol>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204921275.png" alt="image-20210524204921275" style="zoom:100%;" />
<h4 id="the-p-glycoprotein-structure"><a class="markdownIt-Anchor" href="#the-p-glycoprotein-structure"></a> The P-Glycoprotein Structure</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204932275.png" alt="image-20210524204932275" style="zoom:100%;" />
+ Encoded by ABCB1 gene
<h3 id="2-toxicity-and-side-effects-of-antineoplastic-agents"><a class="markdownIt-Anchor" href="#2-toxicity-and-side-effects-of-antineoplastic-agents"></a> 2. Toxicity and side Effects of Antineoplastic Agents</h3>
<p>Normal cells in the body that tend to be injured the most due to chemotherapy are those which have a high growth fraction. Those are bone marrow, GI Tract ,hair follicles, reproductive organs .Leading to the followings:</p>
<ul>
<li>Alopecia (脱发) - hair loss</li>
<li>Myelosuppression  (骨髓功能抑制) - bone marrow loss</li>
<li>Emetic potential (呕吐): disruptive to cells in stomach which causes: Nausea/vomiting</li>
<li>Low WBC count (低白细胞数目) - low immunity</li>
</ul>
<h3 id="3-treatment-induced-tumor"><a class="markdownIt-Anchor" href="#3-treatment-induced-tumor"></a> 3. Treatment-induced tumor</h3>
<p>Many anticancer drugs are mutagens and can cause the rise of neoplasm ten or more years after the original cancer was cured</p>
<h1 id="三-anti-cancer-drugs-and-their-pharmacology"><a class="markdownIt-Anchor" href="#三-anti-cancer-drugs-and-their-pharmacology"></a> 三、Anti-Cancer drugs and their Pharmacology</h1>
<h2 id="why-term-chemtherapy"><a class="markdownIt-Anchor" href="#why-term-chemtherapy"></a> Why term chemtherapy</h2>
<p>Like infective disease</p>
<ul>
<li>Some malignant cells can be cultured</li>
<li>Some malignancies can be transmitted by innoculation</li>
</ul>
<p>Cancer chemotherapy not as successful as antimicrobial chemotherapy</p>
<p>Metabolism in parasite differs qualitatively from host cells, while metabolism in cancer cells differ only quantitatively from normal host cells</p>
<ul>
<li>Hence target selectivity is more difficult in cancer</li>
<li>cancer there is no substantial immune response</li>
<li>Diagnostic complexity: delay in institution of treatment</li>
</ul>
<p>Cancer cells differ from normal cells by</p>
<ul>
<li>Uncontrolled proliferation</li>
<li>De-differentiation loss of function</li>
<li>Invasiveness</li>
<li>Metastasis</li>
</ul>
<h2 id="cell-cycle-and-cancer"><a class="markdownIt-Anchor" href="#cell-cycle-and-cancer"></a> Cell Cycle and Cancer</h2>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135050395.png" alt="image-20210525135050395" style="zoom:100%;" />
The cell cycle and Cancer: both Normal and Cancer cells must traverse before and after cell division.
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135059029.png" alt="image-20210525135059029" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135104615.png" alt="image-20210525135104615" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135120792.png" alt="image-20210525135120792" style="zoom: 67%;" />
<h2 id="classification-of-anti-cancer-drugs"><a class="markdownIt-Anchor" href="#classification-of-anti-cancer-drugs"></a> Classification of Anti-Cancer Drugs</h2>
<h3 id="1-overall-classifications"><a class="markdownIt-Anchor" href="#1-overall-classifications"></a> 1. Overall classifications</h3>
<table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating Agents</td>
<td>Cyclophosphamide, Nitrosourea, Platinum analogs: Cisplatin, Carboplatin</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Cytarabine, Fludarabine, Methotrexate</td>
</tr>
<tr>
<td>Plant alkaloids</td>
<td>Camptothecins, Etoposide, Paclitaxel, Vinblastine</td>
</tr>
<tr>
<td>Antitumor antibiotics</td>
<td>Bleomycin, Doxorubicin, Mitomycin</td>
</tr>
<tr>
<td>Hormonal Agents</td>
<td>Flutamide, Leuprolide,Tamoxifen</td>
</tr>
<tr>
<td>Differential Inducer</td>
<td>Arsenic trioxide, Retinoic acid derivatives</td>
</tr>
<tr>
<td>Gene targeted drugs</td>
<td>Cetuximab, Dasatinib, Gefitinib, Imatinib</td>
</tr>
<tr>
<td>Immunomodulators</td>
<td>Including cytokines and growth factors</td>
</tr>
<tr>
<td>Antiangiogenesis drugs</td>
<td>sorafenib, sunitinib, pazopanib</td>
</tr>
</tbody>
</table>
<h3 id="2-polyfunctional-alkylating-agents"><a class="markdownIt-Anchor" href="#2-polyfunctional-alkylating-agents"></a> 2. Polyfunctional Alkylating Agents</h3>
<h4 id="introduction-and-classification"><a class="markdownIt-Anchor" href="#introduction-and-classification"></a> Introduction and classification</h4>
<p><strong>Alkylation</strong> is the transfer of an alkyl group from one molecule to another.</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525141253371.png" alt="image-20210525141253371" style="zoom:100%;" />
An **alkylating antineoplastic agent** is an alkylating agent used in cancer treatment that attaches an alkyl group (CnH2n+1) to DNA, especially on the guanine base of DNA, at the number 7 nitrogen atom of the purine ring
<p><strong>Alkylating agents classification</strong>:</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525141330998.png" alt="image-20210525141330998" style="zoom:100%;" />
| Categories        | Drugs                                                     |
| ----------------- | --------------------------------------------------------- |
| Nitrogen mustards | Mechlorethamine,Melphalan,Cyclophosphamide,Chlorambu cil  |
| Ethyleneimines    | Thiotepa                                                  |
| Nitrosoureas      | Carmustine,Lomustine                                      |
| Alkylsulfonates   | Busulphan                                                 |
| Platinum          | Coordination complexes: Cisplatin,Carboplatin,Oxaliplatin |
<h4 id="structures-of-alkylating-agents"><a class="markdownIt-Anchor" href="#structures-of-alkylating-agents"></a> Structures of alkylating agents</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142139737.png" alt="image-20210525142139737" style="zoom:100%;" />
#### Alkylation: Mechanisms
<p>Attach an alkyl group to various cellular constituents:</p>
<ul>
<li>DNA—the major attacking subjects: Guanine (N7) , Adenine (N1, N3), Cytosine (N3) and Guanine (O6).</li>
<li>Proteins in various groups, including:
<ul>
<li>Sulfhydryl</li>
<li>Hydrocyl</li>
<li>Phosphate group</li>
<li>Amino</li>
<li>Carboxyl</li>
</ul>
</li>
<li>Carbomoylation of lysine residues by nitrosourea through formation of isocyanates.</li>
<li>Non cell cycle specific, but preferentially attack cells at late G1 and S phases, thus blocking cells at G2</li>
</ul>
<h4 id="mechanisms-of-alkylation-of-dna-guanine"><a class="markdownIt-Anchor" href="#mechanisms-of-alkylation-of-dna-guanine"></a> Mechanisms of Alkylation of DNA Guanine</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142258974.png" alt="image-20210525142258974" style="zoom:100%;" />
#### Mechanisms of Alkylating Action in DNA
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142315443.png" alt="image-20210525142315443" style="zoom: 67%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142322670.png" alt="image-20210525142322670" style="zoom: 67%;" />
<h4 id="resistance-to-alkylating-agents"><a class="markdownIt-Anchor" href="#resistance-to-alkylating-agents"></a> Resistance to Alkylating agents</h4>
<p>Acquired resistance</p>
<ul>
<li>Increased capability to repair DNA lesions</li>
<li>Decreased transport of the alkylating drug into the cell</li>
<li>Increased production of glutathione and glutathione-associated proteins, which are needed to conjugate the alkylating agent, or increased glutathione S-transferase activity, which catalyzes the conjugation.</li>
</ul>
<h3 id="3-platinum-analogs"><a class="markdownIt-Anchor" href="#3-platinum-analogs"></a> 3. Platinum Analogs</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143532638.png" alt="image-20210525143532638" style="zoom:100%;" />
1. Inorganic metal complex
2. They kill tumor cells in all stages of the cell cycle
3. Bind DNA through the formation of intrastrand and interstrand cross-links
4. Leading to inhibition of DNA synthesis and function.
5. N7 Guanine, N3 Adenine,O6 cytosine can also occur.
6. Nephrotoxicity acould be attenuated by i.v. saline infusion.
7. Used for NSCLC, GU, gastric, head and neck, ovarian and bladder cancers
8. Synergistic with other anticancer agents :Alkylating agents, taxanes
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143608863.png" alt="image-20210525143608863" style="zoom: 67%;" />
<h3 id="4-antimetabolic-agents"><a class="markdownIt-Anchor" href="#4-antimetabolic-agents"></a> 4. Antimetabolic Agents</h3>
<ol>
<li>Structural analogues: Neoplastic cells’ metabolic differences – increased susceptibility to actions of antimetabolites.</li>
<li>Most antimetabolites interfere with nucleic acid synthesis or nucleotide synthesis.</li>
<li><strong>Folic acid</strong> antagonist: methotrexate, pemetrexed</li>
<li><strong>Purine</strong> Antagonists: 6-Thiopurines, Fludarabine,</li>
<li><strong>Pyrimidine</strong> Antagonists: 5-Fluorouracil, Cytarabine, gemcitabine</li>
<li>DNA synthesis (S phase–specific)</li>
</ol>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143659938.png" alt="image-20210525143659938" style="zoom:100%;" />
<h4 id="methotrexate"><a class="markdownIt-Anchor" href="#methotrexate"></a> Methotrexate</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143741516.png" alt="image-20210525143741516" style="zoom:100%;" />
**Method of action:** 
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143752339.png" alt="image-20210525143752339" style="zoom:100%;" />
1. binds with high affinity to the active catalytic site of DHFR.
2. interfering with the synthesis of tetrahydrofolate (THF)
3. THF for de novo synthesis of thymidylate, purine nucleotides, and the amino acids serine and methionine.
4. DNA, RNA, and key cellular proteins
<h4 id="5-fluorouracil"><a class="markdownIt-Anchor" href="#5-fluorouracil"></a> 5-Fluorouracil</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143843235.png" alt="image-20210525143843235" style="zoom:67%;" />
<ol>
<li>Uridine derivatives</li>
<li>One derivative, 5-fluoro-2’-deoxyuridine 5’-phosphate (FdUMP),inhibits thymidylate synthase and its cofactor,a tetrahydrofolate derivative,resulting in inhibition of thymidine nucleotide synthesis.</li>
<li>Another derivative, 5-fluorouridine triphosphate is incorporated into RNA, interfering with RNA function.</li>
<li>Cytotoxicity: effects on both RNA and DNA</li>
</ol>
<h4 id="cytarabine-ara-c"><a class="markdownIt-Anchor" href="#cytarabine-ara-c"></a> Cytarabine (ara-C)</h4>
<p>IV administration</p>
<p>S phase specificity: highly schedule-dependent</p>
<p>Clinical Use: almost exclusively for acute myelogenous leukemia</p>
<p>MOA</p>
<ul>
<li>S phase-specific antimetabolite</li>
<li>Biotransformed to active forms: ara-CTP, competitive inhibitor of DNA polymerase.</li>
<li>Blocks DNA synthesis; no effect on RNA or protein synthesis cytarabine incorporated into RNA and DNA – interfering with chain elongation</li>
</ul>
<p>AE (side effect):</p>
<ul>
<li>nausea, alopecia stomatitis , severe myelosuppression</li>
</ul>
<h3 id="5-natural-products-for-cancer-chemotherapy-plant-alkaloids"><a class="markdownIt-Anchor" href="#5-natural-products-for-cancer-chemotherapy-plant-alkaloids"></a> 5. Natural Products for Cancer Chemotherapy: Plant Alkaloids</h3>
<p>function can be totally different</p>
<p>Example: Vincristine, vinblastine, Etoptosides, Camptothecin, Taxanes: Paclitaxel, Doxetaxel</p>
<p><strong>Alkaloid</strong>, any of a class of naturally occurring organic nitrogen-containing bases</p>
<h4 id="vinblastine-and-vincristine"><a class="markdownIt-Anchor" href="#vinblastine-and-vincristine"></a> vinblastine and vincristine</h4>
<p><strong>Resource</strong>: plant products, from periwinkle plant—vinca rosea</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164029948.png" alt="image-20210525164029948" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164043950.png" alt="image-20210525164043950" style="zoom:67%;" />
<p>Function:</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164053841.png" alt="image-20210525164053841" style="zoom:100%;" />
+ **inhibition of tubulin polymerization**, which disrupts assembly of microtubules, an important part of the cytoskeleton and the mitotic spindle. This inhibitory effect results in mitotic arrest in metaphase, bringing cell division to a halt, which then leads to cell death.
<p><strong>Applications</strong>:</p>
<ul>
<li>Vinblastine
<ul>
<li>Cure for:
<ul>
<li>Hodgkin’s lymphoma</li>
<li>Non-Hodgkin’s lymphoma</li>
<li>Breast cancer</li>
<li>Germ cell cancer</li>
</ul>
</li>
<li>AE:
<ul>
<li>Nausea and vomitting</li>
<li>bone marrow suppression</li>
<li>alopecia</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="camptothecins-topotecan-irinotecan"><a class="markdownIt-Anchor" href="#camptothecins-topotecan-irinotecan"></a> Camptothecins: Topotecan, Irinotecan</h4>
<p><strong>Resource</strong>: camptotheca acuminata <strong>tree</strong></p>
<p><strong>MOA</strong>: inhibition of topoisomerase I, the key enzyme responsible for cutting and religating single DNA strands –DNA damage</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164345230.png" alt="image-20210525164345230" style="zoom:100%;" />
<p><strong>Indications（适应症）</strong>:</p>
<ul>
<li><strong>Topotecan (拓扑替康)</strong>–2nd line therapy for: Advanced ovarian cancer, small cell lung cancer</li>
<li><strong>Irinotecan (伊立替康；依立替康；抗癌妥)</strong>—metastatic colorectal cancer as a monotherapy who has failed to 5-FU. Or used as 1st line in combination with 5FU and leucovorin</li>
</ul>
<p><strong>AE</strong>: myelosuppression and diarrhea</p>
<h4 id="taxanes-taxol"><a class="markdownIt-Anchor" href="#taxanes-taxol"></a> Taxanes, Taxol</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164941329.png" alt="image-20210525164941329" style="zoom:100%;" />
+ Paclitaxel
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164949067.png" alt="image-20210525164949067" style="zoom:100%;" />
#### The PK&PD of Taxol
<p>Administration</p>
<ul>
<li>Intravenous(135～350 mg/m2, 3h or 24h)</li>
<li>Intraperitoneal(60～65 mg/m2, every week)</li>
<li>Lipid-soluble</li>
<li>MW=853.91</li>
</ul>
<p>Distribution</p>
<ul>
<li>Liver, lung, pancreas, salivary glands, stomach, heart, muscle, kidney, etc.</li>
<li>Couldn’t pass the blood brain barrier</li>
</ul>
<p>Elimination</p>
<ul>
<li>Cytochrome P450 occur(CYP2C&amp;CYP3A)</li>
<li>Form 6α-hydroxylated paclitaxel</li>
</ul>
<p>Half-Life Elimination</p>
<p>Children: 4.6 to 17 hours (varies with dose and infusion duration)</p>
<p>Adults:</p>
<ul>
<li>3-hour infusion: Mean (terminal): ~13 to 20 hours</li>
<li>24-hour infusion: Mean (terminal): ~16 to 53 hours</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170126311.png" alt="image-20210525170126311" style="zoom:100%;" />
#### Mechanism&Usage
<p>Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division.</p>
<p>Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, <u>paclitaxel stabilizes the microtubule polymer and protects it from disassembly.</u></p>
<p><img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170148030.png" alt="image-20210525170148030" style="zoom:100%;" /><img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170709521.png" alt="image-20210525170709521" style="zoom:100%;" /><br />
Usage</p>
<ul>
<li>Anal cancer, advanced</li>
<li>Bladder cancer, advanced or metastatic</li>
<li>Breast cancer, adjuvant treatment</li>
<li>Breast cancer, metastatic or relapsed</li>
<li>Cervical cancer, advanced</li>
<li>Endometrial cancer, advanced or recurrent</li>
<li>Esophageal cancer, metastatic or unresectable locally advanced</li>
<li>Esophageal/esophagogastric cancer, preoperative chemoradiation</li>
<li>Gastric cancer, metastatic or unresectable locally advanced</li>
<li>Head and neck cancers, advanced</li>
<li>Kaposi sarcoma, AIDS related</li>
<li>Melanoma, advanced or metastatic</li>
<li>Non-small cell lung cancer</li>
<li>Ovarian cancer, advanced</li>
<li>Penile cancer, metastatic</li>
<li>Small cell lung cancer, relapsed/refractory</li>
<li>Soft tissue sarcoma (angiosarcoma), advanced/unresectable</li>
<li>Testicular germ cell tumors, relapsed/refractory</li>
<li>Thymoma/thymic carcinoma, advanced</li>
<li>Thyroid cancer, anaplastic</li>
<li>Unknown primary adenocarcinoma</li>
</ul>
<h4 id="side-effects"><a class="markdownIt-Anchor" href="#side-effects"></a> Side effects</h4>
<p>Anaphylaxis</p>
<p>Alopecia, headache, edema, weakness, etc</p>
<h3 id="9-natural-products-for-cancer-chemotherapy-anti-tumor-antibiotics"><a class="markdownIt-Anchor" href="#9-natural-products-for-cancer-chemotherapy-anti-tumor-antibiotics"></a> 9. Natural Products for Cancer Chemotherapy: Anti-tumor antibiotics</h3>
<p>From microbes: <em>Streptomyces</em> (链霉菌属)</p>
<p>Example:</p>
<ul>
<li>Anthracyclines: doxorubicin, daunorubicin</li>
<li>Mitoxantrone, Dactinomycin</li>
<li>Mitomycin</li>
<li>Bleomycin</li>
</ul>
<p><strong>MOA:</strong></p>
<p>Bind to DNA through intercalation between specific bases and block the synthesis of RNA, DNA, or both</p>
<p>Cause DNA strand scission; and interfere with cell replication</p>
<p>Include the <strong>anthracyclines</strong>, bleomycin, and <strong>mitomycin</strong></p>
<h4 id="anthracyclines"><a class="markdownIt-Anchor" href="#anthracyclines"></a> Anthracyclines</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525171044816.png" alt="image-20210525171044816" style="zoom:100%;" />
<ol>
<li>Inhibition of topoisomerase II;</li>
<li>high-affinity <strong>binding to DNA through intercalation</strong>, with consequent blockade of the synthesis of DNA and RNA, and DNA strand scission;</li>
<li>generation of semiquinone free radicals and oxygen free radicals through an iron-dependent, enzyme-mediated reductive process;</li>
<li>binding to cellular membranes to alter fluidity and ion transport</li>
</ol>
<p><strong>Indications</strong></p>
<ul>
<li><strong>Doxorubicin—Most used one</strong>
<ul>
<li>Solid cancers : breast, endometrium, ovary, testicle, thyroid, stomach, bladder, liver, and lung</li>
<li>Soft tissue sarcomas</li>
<li>Childhood cancers, including neuroblastoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma</li>
<li>Hematologic malignancies
<ul>
<li>acute lymphoblastic leukemia</li>
<li>multiple myeloma</li>
<li>Hodgkin’s and non-Hodgkin’s lymphomas</li>
</ul>
</li>
</ul>
</li>
<li>Daunorubicin—First identified one
<ul>
<li>Acute myeloid leukemia.</li>
<li>Limited for solid tumors</li>
</ul>
</li>
</ul>
<h4 id="mitomycin-c"><a class="markdownIt-Anchor" href="#mitomycin-c"></a> Mitomycin C</h4>
<p><strong>MOA</strong></p>
<ul>
<li>Metabolic activation through an enzyme-mediated reduction;</li>
<li>An alkylating agent that cross-links DNA
<ul>
<li>Active for all cell cycles.</li>
</ul>
</li>
</ul>
<p><strong>Used in combination with radiotherapy</strong>:</p>
<ul>
<li>Hypoxic tumor stem cells , the most sensitive one to MMC.</li>
<li>Squamous cell cancer of the anus</li>
<li>Squamous cell carcinoma of the cervix</li>
<li>Breast, gastric, and pancreatic cancer.</li>
<li>Superficial bladder cancer–intravesical treatment while no systemic toxicity</li>
</ul>
<h4 id="bleomycin"><a class="markdownIt-Anchor" href="#bleomycin"></a> Bleomycin</h4>
<p>Features:</p>
<ul>
<li>Glycopeptide antibiotics isolated from Streptomyces verticillus.</li>
<li>Contains a DNA-binding region and an iron-binding domain</li>
</ul>
<p><strong>MOA:</strong></p>
<ul>
<li>Binding to DNA, which results in <u>single-stranded and double-stranded breaks</u> following free radical formation</li>
<li>Inhibition of DNA biosynthesis.</li>
<li>DNA fragmentation is due to oxidation of a DNA-bleomycin-Fe(II) complex , which leads to chromosomal aberrations</li>
</ul>
<p>Bleomycin is a cell cycle-specific drug that causes accumulation of cells in the <strong>G2 phase</strong> of the cell cycle</p>
<p><strong>Indications:</strong></p>
<ul>
<li>Hodgkin’s and non-Hodgkin’s lymphomas</li>
<li>Germ cell tumor, head and neck cancer, and squamous cell cancer of the skin, cervix, and vulva.</li>
</ul>
<h4 id="hormonal-agents"><a class="markdownIt-Anchor" href="#hormonal-agents"></a> Hormonal Agents</h4>
<p><strong>Estrogen inhibitors</strong>: <strong>Tamoxifen</strong>-antiestrogen, for breast cancer, endometrial cancer</p>
<p><strong>Androgen</strong> inhibitor:</p>
<ul>
<li>Flutamide—binds to Androgen receptor; Prostate cancer</li>
<li>Bicalutamide</li>
</ul>
<h5 id="1-tamoxifen"><a class="markdownIt-Anchor" href="#1-tamoxifen"></a> (1) Tamoxifen</h5>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172442824.png" alt="image-20210525172442824" style="zoom:50%;" />
<ol>
<li>Binds to the ER of the breast tumor</li>
<li>Competitive inhibitor of the ER</li>
<li>Suppresses IGF1 and TGF-β</li>
<li>Therapies for: breast cancer, earlier or metastatic</li>
<li>Prevention for: Breast cancer</li>
</ol>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172655578.png" alt="image-20210525172655578" style="zoom:100%;" />
### 10. Molecularly Targeted Anti-cancer Drugs
<h4 id="pi3k-akt-signaling"><a class="markdownIt-Anchor" href="#pi3k-akt-signaling"></a> PI3K-AKT Signaling</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172934902.png" alt="image-20210525172934902" style="zoom: 50%;" />
<p>PI3K Pathway Inhibitors：</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172950715.png" alt="image-20210525172950715" style="zoom: 50%;" />
<h4 id="genetic-aberrations"><a class="markdownIt-Anchor" href="#genetic-aberrations"></a> Genetic Aberrations</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173019126.png" alt="image-20210525173019126" style="zoom:100%;" />
##### (1) Imatinib (Gleevec)
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173032440.png" alt="image-20210525173032440" style="zoom:100%;" />
**MOA**: inhibition of the tyrosine kinase Bcl/ABL, prevents its phosphorylation by ATP.
<p>Indications:</p>
<ul>
<li>Approved for Ph+ chronic phase of CML (chronic myeloid leukemia),balst crisis that ahs progressed on prior interferon α</li>
<li>Gastrointestinal stromal tumors expressing the c-kit tyrosine kinase</li>
</ul>
<h5 id="2-dasatinib-sprycel"><a class="markdownIt-Anchor" href="#2-dasatinib-sprycel"></a> (2) Dasatinib (Sprycel)</h5>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173303528.png" alt="image-20210525173303528" style="zoom: 67%;" />
<ul>
<li>Crystal structure of Abl kinase domain (blue) in complex with dasatinib (red).</li>
</ul>
<p>The main targets: BCR/ABL, Src, c-Kit, ephrin receptors, and several other tyrosine kinases, but not erbB kinases such as EGFR or Her2</p>
<ul>
<li>Oral inhibitor</li>
<li>Indications: CML , ALL with Ph+</li>
<li>AE: Neutropenia, myelosuppression</li>
</ul>
<h5 id="3-gefitinib-iresa-and-erlotinib-tarcera"><a class="markdownIt-Anchor" href="#3-gefitinib-iresa-and-erlotinib-tarcera"></a> (3) Gefitinib (Iresa) and Erlotinib (Tarcera)</h5>
<ol>
<li>Gefitinib is an <strong>EGFR (epidermal growth factor receptor) inhibitor</strong>, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, such as breast and lung cancers.</li>
<li>Is a drug used for certain <strong>breast, lung</strong> and other cancers</li>
<li>It is <u>not a chemotherapeutic</u> in the traditional sense, since it does not cause the destruction of tumor cells. Instead, gefitnib interferes with the growth and spread of new cancer cells. <u>Anti-tumor but not cytotoxic.</u></li>
<li>Patients who don’t smoke with a bronchoaleolar subtype have a good resposiveness.</li>
<li>Tarcera approved for advanced pancreatic cancer in combination with gemcitabine.</li>
<li>AE: diarrhea, acneifrom skin rash</li>
</ol>
<h5 id="4-cetuximab"><a class="markdownIt-Anchor" href="#4-cetuximab"></a> (4) Cetuximab</h5>
<p><strong>MOA</strong>:</p>
<ul>
<li>Epidermal growth factor receptor inhibitor.</li>
<li>Chimeric monoclonal antibody directly against the extracellular domain of EGFR</li>
</ul>
<p><strong>Indications:</strong></p>
<ul>
<li>For metastetic colorectal cancer in combination with irinotecan or oxaliplatin.</li>
<li>For locally advanced head and neck cancer in combination with radiation therapy.</li>
</ul>
<h4 id="proteasome-and-protein-degradation"><a class="markdownIt-Anchor" href="#proteasome-and-protein-degradation"></a> Proteasome and protein degradation</h4>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173917874.png" alt="image-20210525173917874" style="zoom:100%;" />
##### (1) Bortezomib (Velcade)
<ul>
<li>1st line for mutliple myeloma</li>
<li>2nd line for mantle cell lymphoma</li>
</ul>
<p>the first and only FDA approved anti-cancer agent among proteasome inhibitors</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525174006082.png" alt="image-20210525174006082" style="zoom:67%;" />
<ul>
<li>highly selective</li>
<li>Reversible</li>
<li>26S proteasome complex</li>
<li>Most effective on Myeloma</li>
<li>Effects the bone metabolism in MM</li>
<li>Sensitizes them toward conventional chemotherapy</li>
<li>Prolongs patients’ survival by overcoming resistance to conventional drugs</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525174038754.png" alt="image-20210525174038754" style="zoom:67%;" />
<h4 id="differentiation-inducers"><a class="markdownIt-Anchor" href="#differentiation-inducers"></a> Differentiation Inducers</h4>
<ol>
<li>Retinoic acid derivatives</li>
<li>Arsenic trioxide</li>
</ol>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175114183.png" alt="image-20210525175114183" style="zoom:100%;" />
<p>Specific for APL, acute promyelocytic leukemia by induction of terminal <strong>differentiation</strong> thus losing its ability to proliferate</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175240334.png" alt="image-20210525175240334" style="zoom:100%;" />
#### Arenic Trioxide (As2O3)
<p>Indications: 2nd line for APL with t(15:17) translocation, refractory to ATRA or anthracyclines.</p>
<p><strong>MOA</strong>:</p>
<ul>
<li>degradation of the chimeric protein PML/RARa</li>
<li>mitochondria-dependent cell apoptosis</li>
</ul>
<p>Administration: intravenous.</p>
<p>AE: fatigue, electrocardiographic changes (QT prolongation), arrhythmias.</p>
<h2 id="summary-of-mechanisms-of-action"><a class="markdownIt-Anchor" href="#summary-of-mechanisms-of-action"></a> Summary of Mechanisms of Action</h2>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525152058913.png" alt="image-20210525152058913" style="zoom:100%;" />
<h1 id="四-chemotherapy-pros-and-cons"><a class="markdownIt-Anchor" href="#四-chemotherapy-pros-and-cons"></a> 四、Chemotherapy: Pros and Cons</h1>
<p><strong>A broad spectrum</strong> : almost all kinds of cancers from all organs, including Brain cancer, blood cancers, breast cancer, colon cancer, gastric cancer, lung cancer cancer, prostate cancer….</p>
<p>Kill cancer cells that <u>rapidly grow,</u> or specific genetic presented cancers</p>
<p>More effective when used in <strong>combination</strong> with other drugs or other methods, such as surgery or radiotherapy.</p>
<p><strong>No anticancer drugs</strong> are perfect that kill cancer cells only.</p>
<p>Most adverse effects are:</p>
<ol>
<li>Myelosuppression—anemia, hemorrhage, prone to infection</li>
<li>Somatitis</li>
<li>Alopecia</li>
<li>Gastrointestinal effects.</li>
</ol>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175504627.png" alt="image-20210525175504627" style="zoom:100%;" />
+ Therapeutic targeting of the hallmarks of cancer.
<h1 id="五-tumor-immuno-therapy"><a class="markdownIt-Anchor" href="#五-tumor-immuno-therapy"></a> 五、Tumor-Immuno Therapy</h1>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175644835.png" alt="image-20210525175644835" style="zoom:100%;" />
## Immune system and cancer
<p>The immune system serves as one of the primary defenses against cancer. <u>When normal tissue becomes a tumor or cancerous tissue, new antigens develop on their surface</u>.</p>
<p>These antigens send a signal to immune cells such as the T lymphocytes and macrophages, which in turn <u>directly kill</u> the tumor cells or release substances like <strong>cytokines</strong> that may bring about tumor cell death.</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175715808.png" alt="image-20210525175715808" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175724146.png" alt="image-20210525175724146" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175734353.png" alt="image-20210525175734353" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175742320.png" alt="image-20210525175742320" style="zoom:100%;" />
## Abridged history of cancer immunotherapy: Disappointing until recently
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175753074.png" alt="image-20210525175753074" style="zoom:100%;" />
+ 2011: Ipiliumumab shows overall survival benefit in melanoma
+ 2012-2014: PD1 and PD-L1 blockade has benefit in melanoma and lung
+ cancer 2011-2014: CAR-modified T cells show durable remissions in leukemia
<h2 id="monoclonal-antibodies"><a class="markdownIt-Anchor" href="#monoclonal-antibodies"></a> Monoclonal Antibodies</h2>
<p>Monoclonal antibodies are proteins produced in the laboratory from a single clone of a B−cell, the type of cells of the immune system that make antibodies. When used as a treatment for cancer, there are three general strategies with monoclonal antibodies:</p>
<ul>
<li>One uses the ability of the antibodies to <u>bind to the cancer cells having the tumor antigens on their surface.</u> The immune system will see the cancer cells marked with bound antibodies as foreign and destroy them</li>
<li>A second strategy is to use the antibodies to <u>block the binding of cytokines or other proteins that are needed by the cancerous cells to maintain their uncontrolled growth</u>. Monoclonal antibodies designed to work like this bind to the cytokine receptors that are on the tumor cell surface.</li>
<li>A <u>final</u> strategy involves <u>special antibodies that are linked (conjugated) to a substance that is deadly to the cancer cells</u>. E.G. radioactive isotopes, have been successfully conjugated to antibodies. The antibodies are then used to specifically destroy he tumor cells with the radioactivity or toxic substance</li>
</ul>
<p><strong>Trastuzumab</strong> (曲妥珠单抗)</p>
<ul>
<li>Trastuzumab is a humanized monoclonal antibody produced by recombinant DNA technology that binds specifically to the <u>human epidermal growth factor receptor</u> 2 protein (also known as HER2) that is found on the cell surface of some cancer tumors, most notably breast cancer(25−30% of breast malignancies) and also targets it for destruction by the natural killer cells of immune system.</li>
</ul>
<h2 id="biological-response-modifiers"><a class="markdownIt-Anchor" href="#biological-response-modifiers"></a> Biological response modifiers</h2>
<p>Researchers have been working on <u>stimulating the immune cells</u> during cancer with substances broadly classified as biological response modifiers. <strong>Cytokines</strong> are one such substance. These are proteins that are predominantly released by immune cells upon activation or stimulation.</p>
<p><strong>Aldesleukin</strong></p>
<ul>
<li>Aldesleukin is interleukin, that is used to treat metastasis renal cell carcinoma (a form of kidney cancer) and metastasis melanoma. Aldesleukin is also known as interleukin−2, IL−2</li>
</ul>
<p><strong>Interferons</strong></p>
<ul>
<li>small, natural cytokines produced by leucocytes ,T−lymphocytes, and fibroblasts <u>to activate tumor−specific cytotoxic T−lymphocytes</u>. Thus, tumor cells would be destroyed based on immunotherapy</li>
<li>used to treat cancers such as hairy cell leukemia, malignant melanoma, and Kaposi’s sarcoma (an AIDS−related cancer) as well as many other cancers</li>
</ul>
<h2 id="immune-therapy-can-overcome-tolerance"><a class="markdownIt-Anchor" href="#immune-therapy-can-overcome-tolerance"></a> Immune therapy can overcome tolerance</h2>
<p>Hallmark of cancer: induction of immune tolerance</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184614504.png" alt="image-20210525184614504" style="zoom:100%;" />
### 1. CAR T cells: personalized “serial killer” cells
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184705780.png" alt="image-20210525184705780" style="zoom:50%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184756462.png" alt="image-20210525184756462" style="zoom:67%;" />
<p>Gene transfer technology is used to stably express CARs on T cells, conferring novel antigen specificity</p>
<p>CART19 therapy takes advantage of the cytotoxic potential of T cells thereby killing tumor cells in an antigen-dependent manner</p>
<p>Persistent CART19 cells consist of both effector (cytotoxic) and central memory T cells</p>
<p>T cells are non-cross resistant to chemotherapy</p>
<p>Responses are cytolytic: no swelling!</p>
<h3 id="2-using-synthetic-biology-to-overcome-tolerance-creation-of-bi-specific-car-t-cells"><a class="markdownIt-Anchor" href="#2-using-synthetic-biology-to-overcome-tolerance-creation-of-bi-specific-car-t-cells"></a> 2. Using Synthetic Biology to Overcome Tolerance Creation of Bi-specific CAR T cells</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184908253.png" alt="image-20210525184908253" style="zoom:100%;" />
+ Design of CAR T Cells
<h3 id="3-adult-chronic-leukemia-study-overview"><a class="markdownIt-Anchor" href="#3-adult-chronic-leukemia-study-overview"></a> 3. Adult Chronic Leukemia Study Overview</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184957613.png" alt="image-20210525184957613" style="zoom:100%;" />
Immune Checkpoint Blockade: Mechanism of Action
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185018602.png" alt="image-20210525185018602" style="zoom: 25%;" />
<h3 id="4-a-road-map-of-immunotherapy-agents-in-the-cancer-immune-system-interaction"><a class="markdownIt-Anchor" href="#4-a-road-map-of-immunotherapy-agents-in-the-cancer-immune-system-interaction"></a> 4. A Road Map of Immunotherapy Agents in the Cancer-Immune System Interaction</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185127839.png" alt="image-20210525185127839" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185145400.png" alt="image-20210525185145400" style="zoom:100%;" />
### 5. Immunosuppression is a rate limiting step to effective antitumor immunity
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185258096.png" alt="image-20210525185258096" style="zoom:100%;" />
### 6. Broad activity for anti-PD-L1/PD-1 in human cancer
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185414485.png" alt="image-20210525185414485" style="zoom:100%;" />
### 7. Immune checkpoints: more than PD-1 and CTLA-4
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185436414.png" alt="image-20210525185436414" style="zoom:100%;" />
    </div>

    
    
    

      <footer class="post-footer">
          
          <div class="post-tags">
              <a href="/tags/Molecular-Pharmacology/" rel="tag"><i class="fa fa-tag"></i> Molecular Pharmacology</a>
          </div>

        


        
    <div class="post-nav">
      <div class="post-nav-item">
    <a href="/posts/c0f88b48.html" rel="prev" title="L12 Anesthetics (General and local)">
      <i class="fa fa-chevron-left"></i> L12 Anesthetics (General and local)
    </a></div>
      <div class="post-nav-item">
    <a href="/posts/168f52a5.html" rel="next" title="L15 Antimicrobial Drugs">
      L15 Antimicrobial Drugs <i class="fa fa-chevron-right"></i>
    </a></div>
    </div>
      </footer>
    
  </article>
  
  
  



          </div>
          
    <div class="comments" id="valine-comments"></div>

<script>
  window.addEventListener('tabs:register', () => {
    let { activeClass } = CONFIG.comments;
    if (CONFIG.comments.storage) {
      activeClass = localStorage.getItem('comments_active') || activeClass;
    }
    if (activeClass) {
      let activeTab = document.querySelector(`a[href="#comment-${activeClass}"]`);
      if (activeTab) {
        activeTab.click();
      }
    }
  });
  if (CONFIG.comments.storage) {
    window.addEventListener('tabs:click', event => {
      if (!event.target.matches('.tabs-comment .tab-content .tab-pane')) return;
      let commentClass = event.target.classList[1];
      localStorage.setItem('comments_active', commentClass);
    });
  }
</script>

        </div>
          
  
  <div class="toggle sidebar-toggle">
    <span class="toggle-line toggle-line-first"></span>
    <span class="toggle-line toggle-line-middle"></span>
    <span class="toggle-line toggle-line-last"></span>
  </div>

  <aside class="sidebar">
    <div class="sidebar-inner">

      <ul class="sidebar-nav motion-element">
        <li class="sidebar-nav-toc">
          文章目录
        </li>
        <li class="sidebar-nav-overview">
          站点概览
        </li>
      </ul>

      <!--noindex-->
      <div class="post-toc-wrap sidebar-panel">
          <div class="post-toc motion-element"><ol class="nav"><li class="nav-item nav-level-1"><a class="nav-link" href="#%E4%B8%80-cancer-biology"><span class="nav-text"> 一、Cancer Biology</span></a><ol class="nav-child"><li class="nav-item nav-level-2"><a class="nav-link" href="#what-is-cancer"><span class="nav-text"> What is Cancer</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#what-are-the-difference-between-a-normal-and-cancer-cells"><span class="nav-text"> What are the difference between a normal and cancer cells</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#cancer-therapeutic-modalities"><span class="nav-text"> Cancer Therapeutic Modalities</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#the-log-kill-hypothesis"><span class="nav-text"> The log-kill hypothesis</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#treatment-strategies"><span class="nav-text"> Treatment strategies</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#problems-associated-with-chemotherapy"><span class="nav-text"> Problems associated with chemotherapy</span></a></li></ol></li><li class="nav-item nav-level-1"><a class="nav-link" href="#%E4%B8%89-anti-cancer-drugs-and-their-pharmacology"><span class="nav-text"> 三、Anti-Cancer drugs and their Pharmacology</span></a><ol class="nav-child"><li class="nav-item nav-level-2"><a class="nav-link" href="#why-term-chemtherapy"><span class="nav-text"> Why term chemtherapy</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#cell-cycle-and-cancer"><span class="nav-text"> Cell Cycle and Cancer</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#classification-of-anti-cancer-drugs"><span class="nav-text"> Classification of Anti-Cancer Drugs</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#summary-of-mechanisms-of-action"><span class="nav-text"> Summary of Mechanisms of Action</span></a></li></ol></li><li class="nav-item nav-level-1"><a class="nav-link" href="#%E5%9B%9B-chemotherapy-pros-and-cons"><span class="nav-text"> 四、Chemotherapy: Pros and Cons</span></a></li><li class="nav-item nav-level-1"><a class="nav-link" href="#%E4%BA%94-tumor-immuno-therapy"><span class="nav-text"> 五、Tumor-Immuno Therapy</span></a><ol class="nav-child"><li class="nav-item nav-level-2"><a class="nav-link" href="#monoclonal-antibodies"><span class="nav-text"> Monoclonal Antibodies</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#biological-response-modifiers"><span class="nav-text"> Biological response modifiers</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#immune-therapy-can-overcome-tolerance"><span class="nav-text"> Immune therapy can overcome tolerance</span></a></li></ol></li></ol></div>
      </div>
      <!--/noindex-->

      <div class="site-overview-wrap sidebar-panel">
        <div class="site-author motion-element" itemprop="author" itemscope itemtype="http://schema.org/Person">
    <img class="site-author-image" itemprop="image" alt="向海"
      src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/pixil-frame-0.png">
  <p class="site-author-name" itemprop="name">向海</p>
  <div class="site-description" itemprop="description">希望能活的久一点</div>
</div>
<div class="site-state-wrap motion-element">
  <nav class="site-state">
      <div class="site-state-item site-state-posts">
          <a href="/archives/">
        
          <span class="site-state-item-count">186</span>
          <span class="site-state-item-name">日志</span>
        </a>
      </div>
      <div class="site-state-item site-state-categories">
            <a href="/categories/">
          
        <span class="site-state-item-count">23</span>
        <span class="site-state-item-name">分类</span></a>
      </div>
      <div class="site-state-item site-state-tags">
            <a href="/tags/">
          
        <span class="site-state-item-count">23</span>
        <span class="site-state-item-name">标签</span></a>
      </div>
  </nav>
</div>
  <div class="links-of-author motion-element">
      <span class="links-of-author-item">
        <a href="mailto:zhenyumi@foxmail.com" title="E-Mail → mailto:zhenyumi@foxmail.com" rel="noopener" target="_blank"><i class="fa fa-envelope fa-fw"></i>E-Mail</a>
      </span>
      <span class="links-of-author-item">
        <a href="https://weibo.com/u/2279880515" title="Weibo → https:&#x2F;&#x2F;weibo.com&#x2F;u&#x2F;2279880515" rel="noopener" target="_blank"><i class="fab fa-weibo fa-fw"></i>Weibo</a>
      </span>
      <span class="links-of-author-item">
        <a href="https://twitter.com/ParaDogs_lazy" title="Twitter → https:&#x2F;&#x2F;twitter.com&#x2F;ParaDogs_lazy" rel="noopener" target="_blank"><i class="fab fa-twitter fa-fw"></i>Twitter</a>
      </span>
      <span class="links-of-author-item">
        <a href="https://t.me/Furemu" title="Telegram → https:&#x2F;&#x2F;t.me&#x2F;Furemu" rel="noopener" target="_blank"><i class="fab fa-telegram fa-fw"></i>Telegram</a>
      </span>
  </div>


<!-- none-select-br -->

<p></p>

<!-- hitokoto -->

<div class="hitokoto-title">
	<i class="fa fa-paragraph"></i>
	<b>一言</b>
</div>

<div id="hitokoto">获取中OvO</div>
<i id="hitofrom">获取中OvO</i>

<script src="https://cdn.jsdelivr.net/npm/bluebird@3/js/browser/bluebird.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/whatwg-fetch@2.0.3/fetch.min.js"></script>
<script>
  fetch('https://v1.hitokoto.cn/?c=i')
    .then(function (res){
      return res.json();
    })
    .then(function (data) {
      var hitokoto = document.getElementById('hitokoto');
      hitokoto.innerText = '\xa0\xa0\xa0\xa0\xa0\xa0\xa0' + data.hitokoto;
      var hitofrom = document.getElementById('hitofrom');
      hitofrom.innerText = "——" + data.from + '\xa0'; 
    })
    .catch(function (err) {
      console.error(err);
    })
</script>
      </div>

    </div>
  </aside>
  <div id="sidebar-dimmer"></div>


      </div>
    </main>

    <footer class="footer">
      <div class="footer-inner">
        

        

<div class="copyright">
  
  &copy; 2020 – 
  <span itemprop="copyrightYear">2021</span>
  <span class="with-love">
    <i class="fa fa-heart"></i>
  </span>
  <span class="author" itemprop="copyrightHolder">向海</span>
    <span class="post-meta-divider">|</span>
    <span class="post-meta-item-icon">
      <i class="fa fa-chart-area"></i>
    </span>
      <span class="post-meta-item-text">站点总字数：</span>
    <span title="站点总字数">2.8m</span>
    <span class="post-meta-divider">|</span>
    <span class="post-meta-item-icon">
      <i class="fa fa-coffee"></i>
    </span>
      <span class="post-meta-item-text">站点阅读时长 &asymp;</span>
    <span title="站点阅读时长">42:03</span>
</div><br /> <!-- 换行 -->

<div class="translate-style">
繁/简：<a id="translateLink" href="javascript:translatePage();">繁体
</a>
</div>
<script type="text/javascript" src="/js/tw_cn.js"></script>
<script type="text/javascript">
var defaultEncoding = 2; //网站编写字体是否繁体，1-繁体，2-简体
var translateDelay = 0; //延迟时间,若不在前, 要设定延迟翻译时间, 如100表示100ms,默认为0
var cookieDomain = "https://tding.top/"; //Cookie地址, 一定要设定, 通常为你的网址
var msgToTraditionalChinese = "繁体"; //此处可以更改为你想要显示的文字
var msgToSimplifiedChinese = "简体"; //同上，但两处均不建议更改
var translateButtonId = "translateLink"; //默认互换id
translateInitilization();
</script>

<!-- 网站运行时间的设置 -->
<span id="timeDate">载入天数...</span>
<span id="times">载入时分秒...</span>
<script>
    var now = new Date();
    function createtime() {
        var grt= new Date("06/01/2020 12:00:00");//此处修改你的建站时间或者网站上线时间
        now.setTime(now.getTime()+250);
        days = (now - grt ) / 1000 / 60 / 60 / 24; dnum = Math.floor(days);
        hours = (now - grt ) / 1000 / 60 / 60 - (24 * dnum); hnum = Math.floor(hours);
        if(String(hnum).length ==1 ){hnum = "0" + hnum;} minutes = (now - grt ) / 1000 /60 - (24 * 60 * dnum) - (60 * hnum);
        mnum = Math.floor(minutes); if(String(mnum).length ==1 ){mnum = "0" + mnum;}
        seconds = (now - grt ) / 1000 - (24 * 60 * 60 * dnum) - (60 * 60 * hnum) - (60 * mnum);
        snum = Math.round(seconds); if(String(snum).length ==1 ){snum = "0" + snum;}
        document.getElementById("timeDate").innerHTML = "已正常运行 "+dnum+" 天";
        document.getElementById("times").innerHTML = hnum + " 小时 " + mnum + " 分 " + snum + " 秒 OvO";
    }
setInterval("createtime()",250);
</script>

<br /> <!-- 换行 -->

<!--busuanzi计数-->

    <script async src="//dn-lbstatics.qbox.me/busuanzi/2.3/busuanzi.pure.mini.js"></script>

    <span id="busuanzi_container_site_pv">总访问量<span id="busuanzi_value_site_pv"></span>次</span>
    <span class="post-meta-divider">|</span>
    <span id="busuanzi_container_site_uv">总访客数<span id="busuanzi_value_site_uv"></span>人</span>
    <span class="post-meta-divider">|</span>
<!-- 不蒜子计数初始值纠正 -->
<script>
$(document).ready(function() {

    var int = setInterval(fixCount, 50);  // 50ms周期检测函数
    var countOffset = 20000;  // 初始化首次数据

    function fixCount() {            
       if (document.getElementById("busuanzi_container_site_pv").style.display != "none")
        {
            $("#busuanzi_value_site_pv").html(parseInt($("#busuanzi_value_site_pv").html()) + countOffset); 
            clearInterval(int);
        }                  
        if ($("#busuanzi_container_site_pv").css("display") != "none")
        {
            $("#busuanzi_value_site_uv").html(parseInt($("#busuanzi_value_site_uv").html()) + countOffset); // 加上初始数据 
            clearInterval(int); // 停止检测
        }  
    }
       	
});
</script> 



        
<div class="busuanzi-count">
  <script data-pjax async src="https://busuanzi.ibruce.info/busuanzi/2.3/busuanzi.pure.mini.js"></script>
    <span class="post-meta-item" id="busuanzi_container_site_pv" style="display: none;">
      <span class="post-meta-item-icon">
        <i class="fa fa-eye"></i>
      </span>
      <span class="site-pv" title="总访问量">
        <span id="busuanzi_value_site_pv"></span>
      </span>
    </span>
</div>








      </div>
    </footer>
  </div>

  
  <script src="/lib/anime.min.js"></script>
  <script src="//cdn.jsdelivr.net/gh/theme-next/theme-next-pjax@0/pjax.min.js"></script>
  <script src="//cdn.jsdelivr.net/npm/jquery@3/dist/jquery.min.js"></script>
  <script src="//cdn.jsdelivr.net/gh/fancyapps/fancybox@3/dist/jquery.fancybox.min.js"></script>
  <script src="//cdn.jsdelivr.net/npm/lozad@1/dist/lozad.min.js"></script>
  <script src="//cdn.jsdelivr.net/npm/pangu@4/dist/browser/pangu.min.js"></script>
  <script src="/lib/velocity/velocity.min.js"></script>
  <script src="/lib/velocity/velocity.ui.min.js"></script>

<script src="/js/utils.js"></script>

<script src="/js/motion.js"></script>


<script src="/js/schemes/pisces.js"></script>


<script src="/js/next-boot.js"></script>

<script src="/js/bookmark.js"></script>

  <script>
var pjax = new Pjax({
  selectors: [
    'head title',
    '#page-configurations',
    '.content-wrap',
    '.post-toc-wrap',
    '.languages',
    '#pjax'
  ],
  switches: {
    '.post-toc-wrap': Pjax.switches.innerHTML
  },
  analytics: false,
  cacheBust: false,
  scrollTo : !CONFIG.bookmark.enable
});

window.addEventListener('pjax:success', () => {
  document.querySelectorAll('script[data-pjax], script#page-configurations, #pjax script').forEach(element => {
    var code = element.text || element.textContent || element.innerHTML || '';
    var parent = element.parentNode;
    parent.removeChild(element);
    var script = document.createElement('script');
    if (element.id) {
      script.id = element.id;
    }
    if (element.className) {
      script.className = element.className;
    }
    if (element.type) {
      script.type = element.type;
    }
    if (element.src) {
      script.src = element.src;
      // Force synchronous loading of peripheral JS.
      script.async = false;
    }
    if (element.dataset.pjax !== undefined) {
      script.dataset.pjax = '';
    }
    if (code !== '') {
      script.appendChild(document.createTextNode(code));
    }
    parent.appendChild(script);
  });
  NexT.boot.refresh();
  // Define Motion Sequence & Bootstrap Motion.
  if (CONFIG.motion.enable) {
    NexT.motion.integrator
      .init()
      .add(NexT.motion.middleWares.subMenu)
      .add(NexT.motion.middleWares.postList)
      .bootstrap();
  }
  NexT.utils.updateSidebarPosition();
});
</script>




  




  
<script src="/js/local-search.js"></script>









<script data-pjax>
document.querySelectorAll('.pdfobject-container').forEach(element => {
  let url = element.dataset.target;
  let pdfOpenParams = {
    navpanes : 0,
    toolbar  : 0,
    statusbar: 0,
    pagemode : 'thumbs',
    view     : 'FitH'
  };
  let pdfOpenFragment = '#' + Object.entries(pdfOpenParams).map(([key, value]) => `${key}=${encodeURIComponent(value)}`).join('&');
  let fullURL = `/lib/pdf/web/viewer.html?file=${encodeURIComponent(url)}${pdfOpenFragment}`;

  if (NexT.utils.supportsPDFs()) {
    element.innerHTML = `<embed class="pdfobject" src="${url + pdfOpenFragment}" type="application/pdf" style="height: ${element.dataset.height};">`;
  } else {
    element.innerHTML = `<iframe src="${fullURL}" style="height: ${element.dataset.height};" frameborder="0"></iframe>`;
  }
});
</script>


<script data-pjax>
if (document.querySelectorAll('pre.mermaid').length) {
  NexT.utils.getScript('//cdn.jsdelivr.net/npm/mermaid@8/dist/mermaid.min.js', () => {
    mermaid.initialize({
      theme    : 'forest',
      logLevel : 3,
      flowchart: { curve     : 'linear' },
      gantt    : { axisFormat: '%m/%d/%Y' },
      sequence : { actorMargin: 50 }
    });
  }, window.mermaid);
}
</script>


    <div id="pjax">
  

  
      
<link rel="stylesheet" href="//cdn.jsdelivr.net/npm/katex@0/dist/katex.min.css">
  <script src="//cdn.jsdelivr.net/npm/katex@0/dist/contrib/copy-tex.min.js"></script>
  <link rel="stylesheet" href="//cdn.jsdelivr.net/npm/katex@0/dist/contrib/copy-tex.min.css">


  
  <script src="//cdn.jsdelivr.net/npm/quicklink@1/dist/quicklink.umd.js"></script>
  <script>
      window.addEventListener('load', () => {
      quicklink({
        timeout : 3000,
        priority: true,
        ignores : [uri => uri.includes('#'),uri => uri === 'https://zhenyumi.github.io/posts/6c8073ce.html',]
      });
      });
  </script>


<script>
NexT.utils.loadComments(document.querySelector('#valine-comments'), () => {
  NexT.utils.getScript('//cdn.jsdelivr.net/npm/valine@1/dist/Valine.min.js', () => {
    var GUEST = ['nick', 'mail', 'link'];
    var guest = 'nick,mail,link';
    guest = guest.split(',').filter(item => {
      return GUEST.includes(item);
    });
    new Valine({
      el         : '#valine-comments',
      verify     : false,
      notify     : true,
      appId      : 'ErV27FWAFsY2HDPhLVjeIcfR-MdYXbMMI',
      appKey     : 'YyUrjqWLM53k8C1tPcKNaQFN',
      placeholder: "Leave Something?",
      avatar     : 'mm',
      meta       : guest,
      pageSize   : '10' || 10,
      visitor    : false,
      lang       : 'zh-ch' || 'zh-cn',
      path       : location.pathname,
      recordIP   : true,
      serverURLs : ''
    });
  }, window.Valine);
});
</script>

    </div>
</body>
</html>
